Loading...
XNASSCNI
Market cap857mUSD
Dec 23, Last price  
3.35USD
1D
-1.47%
1Q
-6.94%
Jan 2017
0.00%
IPO
-16.04%
Name

BiondVax Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XNAS:SCNI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
42.99%
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L+12.15%
-28,951,718-35,653,351-29,513,243-28,446,630-39,730,459-35,258,771-121,745,088-81,165,493-397,895,1360-12,847,649-5,796,000-6,500,000
CFO
-9m
L+29.14%
-36,275,947-26,765,804-15,443,403-27,743,158-39,995,355-37,059,334-35,412,524-199,289,498-280,793,847-233,049,6720-7,265,000-9,382,000

Profile

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
URL
https://www.biondvax.com/
IPO date
Jun 07, 2007
Employees
33
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
5,210
5,765
Unusual Expense (Income)
NOPBT
(5,210)
(5,765)
NOPBT Margin
Operating Taxes
334
Tax Rate
NOPAT
(5,210)
(6,099)
Net income
(6,500)
12.15%
(5,796)
-54.89%
(12,848)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
139
932
22,175
BB yield
-59.76%
-167.02%
-6,685.60%
Debt
Debt current
396
382
Long-term debt
21,358
22,620
22,163
Deferred revenue
Other long-term liabilities
96
5,329
Net debt
16,884
8,927
4,797
Cash flow
Cash from operating activities
(9,382)
(7,265)
CAPEX
(637)
(836)
Cash from investing activities
(637)
(836)
Cash from financing activities
1,086
6,776
21,783
FCF
(4,538)
(4,621)
31,599
Balance
Cash
4,870
14,075
17,365
Long term investments
Excess cash
4,870
14,075
17,365
Stockholders' equity
(124,075)
(117,842)
(117,226)
Invested Capital
140,163
142,953
149,234
ROIC
ROCE
EV
Common stock shares outstanding
391
189
141
Price
0.60
-79.89%
2.96
25.96%
2.35
-16.37%
Market cap
233
-58.32%
558
68.24%
332
6.52%
EV
17,117
9,485
5,129
EBITDA
(4,696)
(5,203)
EV/EBITDA
Interest
317
Interest/NOPBT